NeuroPace (NASDAQ:NPCE - Get Free Report) is expected to release its earnings data after the market closes on Tuesday, March 4th. Analysts expect NeuroPace to post earnings of ($0.25) per share and revenue of $21.14 million for the quarter. Persons that wish to register for the company's earnings conference call can do so using this link.
NeuroPace Price Performance
Shares of NPCE traded up $0.39 during trading hours on Friday, reaching $12.95. The company had a trading volume of 134,520 shares, compared to its average volume of 116,780. The company has a market capitalization of $386.53 million, a price-to-earnings ratio of -12.95 and a beta of 2.05. NeuroPace has a 12-month low of $5.45 and a 12-month high of $17.10. The firm has a 50 day simple moving average of $12.66 and a 200-day simple moving average of $9.60. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.
Insider Buying and Selling
In other news, major shareholder Ltd. Kck sold 5,270,845 shares of the company's stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Martha Morrell sold 3,200 shares of the stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $15.01, for a total transaction of $48,032.00. Following the completion of the sale, the insider now directly owns 87,062 shares of the company's stock, valued at $1,306,800.62. This trade represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 5,352,479 shares of company stock valued at $50,670,217. Insiders own 22.20% of the company's stock.
Analyst Ratings Changes
Several research firms have recently issued reports on NPCE. Wells Fargo & Company lifted their price target on NeuroPace from $13.00 to $17.00 and gave the stock an "overweight" rating in a research note on Thursday, January 30th. UBS Group assumed coverage on NeuroPace in a research report on Tuesday, January 21st. They set a "buy" rating and a $17.00 price objective for the company. Finally, JPMorgan Chase & Co. boosted their target price on shares of NeuroPace from $9.00 to $14.00 and gave the company an "overweight" rating in a research note on Tuesday, December 17th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $14.80.
Check Out Our Latest Report on NeuroPace
About NeuroPace
(
Get Free Report)
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Further Reading
Before you consider NeuroPace, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeuroPace wasn't on the list.
While NeuroPace currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
